CDK4 and colorectal cancer: Here, we have undertaken an in-depth, unbiased metabolomics approach to assess in greater detail the metabolic reprogramming undergone by HCT116 colorectal cancer cells exposed to either the CDK4/6i Palbociclib, the glutaminase inhibitor Telaglenastat, or their combination.